A 64-year-old woman who was recently diagnosed with colorectal cancer is brought to the emergency department with substernal chest pain and shortness of breath.
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
A 3-month risk for a thromboembolic event was assessed using a pulmonary embolism rule-out criteria strategy and compared with a conventional strategy in patients with a low clinical probability of pulmonary embolism.
Acute pulmonary embolism may be managed in an outpatient setting when the patient has a low risk for mortality.
Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.
Surgical left atrial appendage occlusion is associated with a lower risk for thromboembolism-related hospital readmission in older patients with atrial fibrillation who undergo cardiac surgery.
Patients diagnosed with an intermediate-risk pulmonary embolism may be able to start oral anticoagulation therapy after completing 72 hours of heparin therapy during hospitalization.
Catheter-directed thrombolysis vs systemic thrombolysis strategies show different risk outcomes for patients with intermediate-risk pulmonary embolism.
Several clinical predictors of pediatric pulmonary embolism have been identified.
Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement
A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.
The 10 mg dose of rivaroxaban substantially lowered the risk for recurrent venous thromboembolism.
The Cardiology Advisor Articles
- The Mounting Evidence Against Electronic Cigarette Use
- Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
- Oxygen Therapy in Acute MI Not Associated With Clinical Benefit
- Nonpsychotic Cannabinoids in Hypertension: Benefits and Harms
- ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation